Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.

British journal of cancer - 20 May 2008

Widmer N, Decosterd L A, Leyvraz S, Duchosal M A, Rosselet A, Debiec-Rychter M, Csajka C, Biollaz J, Buclin T

Abstract excerpt

Imatinib has revolutionised the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal tumours (GIST). Using a nonlinear mixed effects population model, individual estimates of pharmacokinetic parameters were derived and used to estimate imatinib exposure (area under the curve,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Benzamides
Share to Gastrointestinal Stromal Tumors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Protein-Tyrosine Kinases

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 18475296
DOI: 10.1038/sj.bjc.6604355
PMCID: PMC2391118

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18475296-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.PMID 18475296Read ↗

CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients.Semantic proximity Read ↗

Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.Semantic proximity Read ↗

Influence of Cytochrome P450, ABC and SLC Gene Polymorphisms on Imatinib Therapy Outcome of Patients with Gastrointestinal Stromal Tumours (GIST).Semantic proximity Read ↗

Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and AdultsSemantic proximity Read ↗

Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example.Semantic proximity Read ↗

Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia.Semantic proximity Read ↗

Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.Semantic proximity Read ↗

Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.Semantic proximity Read ↗

Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.Semantic proximity Read ↗

Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study.Semantic proximity Read ↗

Metabolism and disposition of imatinib mesylate in healthy volunteers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.